SCHEMBL13824271

SCHEMBL13824271

C=C1COc2ccc(C(=C)OCCO)cc2C(=C/CCN2CCC(O)(c3ccc(Cl)cc3)CC2)/C1=C/C=C\C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR1 P32246 2/20 0.38
▸ DRD2 P14416 8/20 0.35
▸ ADRA1A P35348 2/20 0.35
▸ DRD3 P35462 2/20 0.35
▸ CHRM2 P08172 2/20 0.35
▸ CCR5 P51681 1/20 0.35
▸ MEN1 O00255 1/20 0.33
▸ CACNA1F O60840 1/20 0.33
▸ KCNK2 O95069 1/20 0.33
▸ ABCB11 O95342 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ ADRB2 P07550 1/20 0.33
▸ CHRM4 P08173 1/20 0.33
▸ ABCB1 P08183 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ CHRM5 P08912 1/20 0.33
▸ ADRA2A P08913 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CHRM1 P11229 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10287597 0.91 CCR1 (0.36) CCR1DRD2ADRA1ACHRM2CCR5
SCHEMBL13824278 0.90 CCR1 (0.38) CCR1DRD2ADRA1ACHRM2CCR5
SCHEMBL14579853 0.88 CCR1 (0.37) CCR1DRD2ADRA1ADRD3CHRM2
SCHEMBL12121744 0.87 DRD2 (0.39) CCR1DRD2ADRA1ADRD3CHRM2
SCHEMBL13824486 0.87 CCR1 (0.39) CCR1DRD2ADRA1ACHRM2CCR5
SCHEMBL12121691 0.86 CCR1 (0.41) CCR1DRD2ADRA1ADRD3HTR1A
SCHEMBL13824277 0.84 CCR1 (0.40) CCR1DRD2ADRA1ADRD3HTR1A
SCHEMBL14420162 0.83 CCR1 (0.54) CCR1DRD2ADRA1ADRD3CHRM2
SCHEMBL10287599 0.81 CCR1 (0.56) CCR1DRD2ADRA1ADRD3CHRM2
SCHEMBL12121693 0.81 CCR1 (0.35) CCR1CHRM2CCR5HRH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7541365-B2 Chemokine receptor antagonists and methods of use therefor MILLENNIUM PHARMACEUTICALS, INC. (US) 2009-06-02 — — US disclosed
US-20070060592-A1 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation MILLENNIUM PHARMACEUTICALS, INC. 2007-03-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070060592-A1 heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation THPO, NFATC1, HPGDS CCR1 19/4885DRD2 1061/4885ADRA1A 172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback